These results indicate that administration of a low-dose SGLT2 inhibitor prior to ischemic stroke attenuates BBB disruption, resulting in lower infarct volume and attenuation of neurological symptoms after ischemic stroke. This evidence concerns the gene SLC5A2 and ischemic stroke.